Literature DB >> 20217526

Nanoparticle technologies for cancer therapy.

Frank Alexis1, Eric M Pridgen, Robert Langer, Omid C Farokhzad.   

Abstract

Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217526     DOI: 10.1007/978-3-642-00477-3_2

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  75 in total

1.  Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.

Authors:  T Nie; C C Wong; N Alston; P Aro; P P Constantinides; B Rigas
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

3.  Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.

Authors:  Bryan Hoang; Mark J Ernsting; Mami Murakami; Elijus Undzys; Shyh-Dar Li
Journal:  Int J Pharm       Date:  2014-05-20       Impact factor: 5.875

4.  Using synthetically modified proteins to make new materials.

Authors:  Leah S Witus; Matthew B Francis
Journal:  Acc Chem Res       Date:  2011-08-03       Impact factor: 22.384

Review 5.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

Review 6.  Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications.

Authors:  Yongjian Liu; Michael J Welch
Journal:  Bioconjug Chem       Date:  2012-02-06       Impact factor: 4.774

Review 7.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

8.  Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.

Authors:  Hugo Oliveira; Julie Thevenot; Elisabeth Garanger; Emmanuel Ibarboure; Pilar Calvo; Pablo Aviles; Maria Jose Guillen; Sébastien Lecommandoux
Journal:  Pharm Res       Date:  2013-11-28       Impact factor: 4.200

9.  Polymer directed self-assembly of pH-responsive antioxidant nanoparticles.

Authors:  Christina Tang; Devang Amin; Phillip B Messersmith; John E Anthony; Robert K Prud'homme
Journal:  Langmuir       Date:  2015-03-20       Impact factor: 3.882

10.  Scolicidal and apoptotic activities of albendazole sulfoxide and albendazole sulfoxide-loaded PLGA-PEG as a novel nanopolymeric particle against Echinococcus granulosus protoscoleces.

Authors:  Marziyeh Naseri; Abolfazl Akbarzadeh; Adel Spotin; Nagibeh Asl Rahnemaii Akbari; Mahmoud Mahami-Oskouei; Ehsan Ahmadpour
Journal:  Parasitol Res       Date:  2016-09-14       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.